Addition of Enzalutamide to Leuprolide and Definitive Radiation Therapy Is Tolerable and Effective in High-Risk Localized or Regional Nonmetastatic Prostate Cancer: Results From a Phase 2 Trial

Addition of Enzalutamide to Leuprolide and Definitive Radiation Therapy Is Tolerable and Effective in High-Risk Localized or Regional Nonmetastatic Prostate Cancer: Results From a Phase 2 Trial

Background: Enzalutamide is an antiandrogen used to treat both metastatic and nonmetastatic prostate cancer. Here we present results from a phase 2 trial designed to determine the safety, tolerability, and efficacy of adding enzalutamide to standard androgen deprivation therapy with radiation therap...

Full description

Bibliographic Details
Main Authors: Kevin Shee, MD, PhD, Claire M. de la Calle, MD, Albert J. Chang, MD, PhD, Anthony C. Wong, MD, PhD, Felix Y. Feng, MD, Alexander R. Gottschalk, MD, PhD, Peter R. Carroll, MD, MPH, Hao G. Nguyen, MD, PhD
Format: Article
Language:English
Published: Elsevier 2022-09-01
Series:Advances in Radiation Oncology
Online Access:http://www.sciencedirect.com/science/article/pii/S2452109422000483

Internet

http://www.sciencedirect.com/science/article/pii/S2452109422000483

Similar Items